The Journal of the Pharmacy Society of Wisconsin
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact

​Literature Review of Fixed and Weight-Based Dosing of 4-Factor Prothrombin Complex Concentrate in Achievement of Hemostasis in Adult Patients Taking Factor Xa Direct Oral Anticoagulants 

by Ivy Cannella, 2022 PharmD Candidate, Carolyn Villareal, PharmD, BCPS

"Major bleeding is an unfortunate risk of anticoagulation therapy. Currently, andexanet alfa is the only approved agent for reversal of factor Xa DOACs.1 Other agents, including 4F-PCC, have been used off-label for the reversal of DOACs in the setting of major bleeding. Factor Xa DOACs, which include rivaroxaban, apixaban, edoxaban, and betrixaban, target Xa to block the coagulation cascade. 4F-PCC can be used as a reversal agent because it contains coagulation factors II, VII, IX, and X, as well as proteins C and S.2 An additional benefit to using 4F-PCC over other approved reversal agents is a significant cost savings. Wilsey et al. calculated the cost of a dose of andexanet alfa to be $58,080, a 50 unit/kg dose of 4F-PCC to be $6,885, and a 25 unit/kg dose of 4F-PCC to be $3,443 for an 85-kg patient.3"
​
Keywords: Edoxaban, Factor Xa, Rivaroxaban, Warfarin, Pharmacists, Apixaban, Betrixaban, Cost Savings, Off-Label Use, Wisconsin, Blood, Coagulation Factors, Hemorrhage, Anticoagulants

​Download PDF 

2022 March/April Table of Contents 

The Journal of the Pharmacy Society of Wisconsin


Past Issues

2020
2021
​2022
2019
2018
2017

About PSW

www.pswi.org

Contact Us

thejournal@pswi.org
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact